Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

Fig. 2

Percentage of individuals achieving non-HDL-C, LDL-C, and ApoB targets at week 24 (ITT). Non-HDL-C: 100 mg/dL = 2.59 mmol/L; LDL-C: 70 mg/dL = 1.81 mmol/L. Apo apolipoprotein, HDL-C high-density lipoprotein cholesterol, ITT intent-to-treat, LDL-C low-density lipoprotein cholesterol, UC usual care

Back to article page